As described above, unlike PD-L1 IHC, CGP assessable biomarkers (MSI and TMB) are largely useful in practice to guide anti-PD-(L)1 monotherapy outside of approved tumor types in patients with later-line tumors. The gene discussed is CD274; the disease is neoplasm.